Combination Vaccines Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global Combination Vaccines Market is Segmented By Product Type (Inactivated vaccine, Live attenuated vaccine), By Age Group (Children, Adults), By Combination Type (DTaP/IPV/Hep B, DTaP/Hib/IPV, MMR II, Hep B-Hib, Others), By Distribution Channel (Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Combination Vaccines Market Overview

Global Combination Vaccines by DataM Intelligence estimates the market to grow at a CAGR of 11% during the forecast period 2024-2031. Demand from Hospital Pharmacies, Retailer Pharmacies in North America is rising. Competitive rivalry intensifies with Astrazeneca, GlaxoSmithKline plc, Crunchbase Inc and others operating in the market.

Combination vaccines are a mixture of two or more vaccines that can be administered individually into a single vaccine shot. This allows individuals to get fewer shots to get benefited for more number of diseases, easing the process for both the patients and the administrators with the administration of a single shot. Therefore, human combination vaccines market has an advantage over individual vaccines.

Combination Vaccines Market Summary

For More Insights about the Market Request Free Sample

Combination Vaccines Market Trends and Dynamics

Combination Vaccines Market growth is driven by the increase in the prevalence of infectious diseases, rise in paediatric population and rising interest of manufacturers in developing novel vaccines to target a wide range of diseases.

Increase in the prevalence of infectious diseases coupled with rising interest of manufacturers in developing novel vaccines is expected to hold the largest share in this market segment

Since infants do not have a fully developed immune system at early stages of life, they are more vulnerable to many infectious diseases. For instance, the Centers for Disease Control and Prevention (CDC) reported that approximately 3.1% children population in the age group 5-11 years was in fair or poor health in the U.S in 2019. This further leads to an increase in the demand for combination vaccines thus, driving the market. Also, an increase in antiviral drug resistance has shifted the market trend towards combination vaccines as these vaccines eliminate the problem of drug resistance. For instance, according to a review article published in Nature, a scientific journal in 2021, use of vaccines reduces the spread of antimicrobial drug resistance as they are used specifically for a given infectious antigen.

Moreover, rising interest of manufacturers in developing novel vaccines to target a wide range of diseases boost the growth potential of human combination vaccine market. For instance, in September 2020, Sanofi Pasteur, launched Tetraxim (DTaP-IPV) as the first full-dose DTaP booster vaccine for children that provides protection against four infectious diseases- Diptheria, Tetanus, Whooping cough, and Polio.

Threat of bioterrorism and stringent regulatory policies for the approval of novel combination vaccine is expected hamper the market growth

Bioterrorism refers to the use of biological agents such as bacteria, fungus, and virus to disrupt human life. Since these biological agents are unpredictable it is difficult to control them. Bioterrorism can easily spread through the route of vaccines hence; regulatory authorities scrutinise the vaccine development process to avoid any mishaps. For instance, the U.S Food and Administration authority has been directed by the Public Health Security and Bioterrorism Preparedness and Response Act of 2002 to protect the public against bioweapons associated with vaccines, diagnostic tools, and drugs in the U.S. The U.S. FDA has set out a complex and multistep process for assessing the safety, efficiency, and immunogenicity of the vaccine before approval of licensure for a particular vaccine, followed by post-approval surveillance.

COVID-19 Impact Analysis on Combination Vaccines Market

Coronavirus disease 2019 (COVID‐19) is an acute respiratory infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 has moved from a regional crisis to a global pandemic in just a few weeks. The World Health Organization (WHO) declared COVID-19 as a pandemic on March 11, 2020. There has been a tremendous amount of effort put into developing new treatments and vaccines to cure the infection. Within a few weeks of research, companies started coming up with drugs and treatments to treat the infection.

Combination Vaccines Market Segmentation Analysis

The inactivated vaccine segment is expected to hold the largest share in this market segment

Inactivated vaccine segment is anticipated to grow over the forecast period due to its high adoption and acceptance as an efficient human combination vaccine. Also, stability of inactivated vaccine makes it the perfect candidate to be used for treatment of infectious diseases as it can be stored and transported easily in lyophilised form. For instance, according to Global Vaccine Market report by World Health Organization, in 2017 the global demand for D&T vaccine (Diptheria and Tetanus) was approximately 945 million doses wherein DTwP-HepB-Hib vaccine accounted for 33% of total D&T vaccine.

Global Combination Vaccines Market Geographical Share

North America region holds the largest market share of global combination vaccines market

A boost in R&D activities and increasing technological advancements propel the market growth of human combination vaccine in North America. For instance, in 2019 three licensed DTaP combinations were readily available in North America for providing immunity against diphtheria, tetanus, and whooping cough (acellular pertussis) in children. These combination vaccines include Infanrix manufactured by GlaxoSmithKline, and Tripedia and Daptacel manufactured by Sanofi Pasteur. Also, booster combination vaccines Boostrix and Adacel are widely available for use in adults in North American region which drives the combination vaccine market growth in this region.

Additionally, the U.S government has been actively involved in vaccine awareness initiatives which is another factor that drives the growth of human combination vaccine. For instance, on 25th May 2021, the Baker-Polite Administration partnered up with the Museum of Science, Boston with an aim of increasing access to COVID-19 vaccines. The administration announced USD 4.7 million investment for its Vaccine Equity Initiative.

Combination Vaccines Companies & Competitive Landscape

The global combination vaccines market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Sanofi, Cadila Healthcare Ltd., GlaxoSmithKline plc, CSL Ltd., Mitsubishi Tanabe Pharma Corp., DAIICHI SANKYO COMPANY, LIMITED, Merck & Co., Crunchbase Inc., Mass Biologics, Astrazeneca.

Astrazeneca

Overview: AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

Product Portfolio: It includes products like Oxford/AstraZeneca COVID-19 vaccine (ChAdOx1-S [recombinant] vaccine).